search button

Non‑invasive imaging of Toll‑like receptor 5 expression using 131I‑labeled mAb in the mice bearing H22 tumors

  • Authors:
    • Changya Yang
    • Qingying Yun
    • Hukui Sun
    • Guangjie Yang
    • Ting Liang
    • Chao Zhang
    • Jing Song
    • Jiankui Han
    • Guihua Hou

  • View Affiliations

  • Published online on: April 2, 2014     https://doi.org/10.3892/ol.2014.2025
  • Pages: 1919-1924
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Toll‑like receptor 5 (TLR5) is overexpressed in several cancers and metastases, and presents an enticing target for molecular imaging of primary tumors. In the present study, 131I‑anti‑TLR5 monoclonal antibody (mAb) was evaluated for its use as a novel radiotracer for imaging hepatocarcinoma in mice bearing H22 tumors. The expression of TLR5 was analyzed by quantitative polymerase chain reaction and immunohistochemistry. The anti‑TLR5 mAb and isotype immunoglobulin G (IgG) were radiolabeled with iodine‑131 by the Iodogen method. The in vitro stability of iodinalized probes was determined in serum or saline for a series of times, and then evaluated with radio‑thin‑layer chromatography. The biodistribution study and autoradiography were performed in H22 tumor‑bearing mice. It was found that H22‑xenografted tumor tissue exhibited a higher level of TLR5 expression compared with normal liver tissues. 131I‑anti‑TLR5 mAb and 131I‑IgG were obtained subsequent to purification, with high radiochemical purity (>95%), and remained stable for 48 h in human serum. The target‑to‑non‑target ratio in the 131I‑anti‑TLR5 mAb group was significantly higher compared with the 131I‑IgG group. The biodistribution study and autoradiography demonstrated that 131I‑anti‑TLR5 mAb was specifically retained in hepatocarcinoma with a high tumor uptake. Altogether, these results show that 131I‑anti‑TLR5 mAb is capable of detecting lesions in a TLR5‑expressing tumor, with high target selectivity, and may offer a promising agent for hepatocarcinoma diagnosis and encourage further investigation.
View Figures
View References

Related Articles

Journal Cover

June-2014
Volume 7 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yang C, Yun Q, Sun H, Yang G, Liang T, Zhang C, Song J, Han J and Hou G: Non‑invasive imaging of Toll‑like receptor 5 expression using 131I‑labeled mAb in the mice bearing H22 tumors. Oncol Lett 7: 1919-1924, 2014.
APA
Yang, C., Yun, Q., Sun, H., Yang, G., Liang, T., Zhang, C. ... Hou, G. (2014). Non‑invasive imaging of Toll‑like receptor 5 expression using 131I‑labeled mAb in the mice bearing H22 tumors. Oncology Letters, 7, 1919-1924. https://doi.org/10.3892/ol.2014.2025
MLA
Yang, C., Yun, Q., Sun, H., Yang, G., Liang, T., Zhang, C., Song, J., Han, J., Hou, G."Non‑invasive imaging of Toll‑like receptor 5 expression using 131I‑labeled mAb in the mice bearing H22 tumors". Oncology Letters 7.6 (2014): 1919-1924.
Chicago
Yang, C., Yun, Q., Sun, H., Yang, G., Liang, T., Zhang, C., Song, J., Han, J., Hou, G."Non‑invasive imaging of Toll‑like receptor 5 expression using 131I‑labeled mAb in the mice bearing H22 tumors". Oncology Letters 7, no. 6 (2014): 1919-1924. https://doi.org/10.3892/ol.2014.2025